Loretta Little focuses on investment opportunities in the life sciences such as medical devices, digital health and scientific instrumentation. Her portfolio includes consumer technology, software and advanced materials companies. Exits include AbSci (IPO 2021), C-SATS (acquired by J&J/Ethicon), Clarisonic (acquired by L’Oreal), Mirador Biomedical (acquired by Centurion Medical Products) and Amnis (acquired by EMD Millipore). She oversees WRF Capital’s investments in 2Morrow, AdaptX, Alpenglow Biosciences, Birch.ai, DirectAMS, MajorBoost, Medcurity, TransformativeMed, Watershed Therapeutics and Wavely Diagnostics.
Previously, Ms. Little served as senior technology licensing manager at Washington Research Foundation (WRF). Before joining WRF, she worked as a marketing manager for a biotechnology company and as a market consultant.
Ms. Little received an MBA from the University of Arizona and a B.A. in zoology from Pomona College. She currently serves as a board member of Alliance of Angels, Buerk Center for Entrepreneurship at the University of Washington, Life Science Washington and Life Science Washington Institute.